Contractor profile

Glaxosmithkline, LLC

FY2026 ended Sep 30 · data still posting · data as of 2026-11-01†

† DoD contract data posts to USAspending about 90 days after award.

prime recipient of federal awards · Subsidiary of GSK plc · United Kingdom Inferred · UEI FRHTPHMZMX47 Source
$1.1B
Obligated
FY2026 · data still posting
5
Funding agencies
100%
From Health and Hum…
3%
Non-competed
4
States
4%
In North Carolina
6
Industries

In FY2026, Glaxosmithkline, LLC received $1.1B in federal awards from 5 agencies, 100% of it from the Department of Health and Human Services, with 4% of the work performed in North Carolina. Across FY2020 to FY2026 its recorded total is $9.2B. FY2026 ended Sep 30 and its data is still posting. Computed

Where this money comes from

Source
FUNDING AGENCIES
GLAXOSMITHKLINE, LLC
HHS
$1.1B
4 other agencies
$0B
Glaxosmithkline, LLC
$1.1B
FY2026 obligated
band width = obligations · FY2026 · source: USASpending.gov

Where the work lands

Source
North Carolina$40.5M
Georgia$58.2K

State breakdown available for 3% of obligations shown

Key takeaways

Computed
FY2026 ended Sep 30 · data still posting · data as of 2026-11-01
  • Glaxosmithkline, LLC received $1.1B in federal obligations in FY2026 (data still posting), compared with $980.5M in FY2025.
  • It ranked #89 among federal contractors by contract obligations in FY2026 (data still posting).
  • The Department of Health and Human Services accounted for 99% of it.
  • Of its $1.1B in contract obligations, 3% was non-competed, based on FPDS extent-competed codes.

Obligations by year

Computed
$1.3B
FY20
$1.1B
FY21
$2.8B
FY22
$850.1M
FY23
$1.2B
FY24
$980.5M
FY25
$1.1B
FY26 partial
▼ 25%
FY20 to FY25

Awards

Source

Largest active awards by total value

Awards whose period of performance overlaps FY2026, by the amount obligated on each so far.

No award on record was active in FY2026.

Largest FY2026 awards

Awards that started in FY2026, by the amount obligated on each so far.

No award on record started in FY2026.

What it does (NAICS / PSC)

Pharmaceutical Preparation Manufacturing$1.1B
Research and Development in Biotechnology (except Nanobiotechnology)$3.4M
Medicinal and Botanical Manufacturing$513.7K
Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers$74.8K

Competition

3%non-competed (often called no-bid), of $1.1B in contract obligations in FY2026Computed

This describes how contracts were awarded, not wrongdoing.

Similar federal contractors

Computed
Mckesson Corporation$14.9B
Merck Sharp & Dohme LLC$2.3B
Pfizer Inc$1.1B
Sanofi Vaccines US Inc.$734.4M
Emergent Biosolutions Canada Inc$118.3M
Exelan Pharmaceuticals Inc$96.2M
Canadian Commercial Corporation$16.4M
Trillamed LLC$1.1M

Corporate family

Single registration: no combined family.

Political contributions

Glaxosmithkline LLC PAC (Gsk PAC)Inferredgave$498.5Kto members of CongressSource
Richard Hudson (Republican)$31K
Lloyd Smucker (Republican)$23.5K
Earl L. "Buddy" Carter (Republican)$18.5K
Brett Guthrie (Republican)$16.5K
Madeleine Dean (Democrat)$14K
Virginia Foxx (Republican)$13.5K
Gregory F. Murphy (Republican)$13K
Steve Daines (Republican)$12.5K
John Joyce (Republican)$12.5K
Bill Cassidy (Republican)$11K

linked through public filings, not a claim of coordination. contribution reported to the FEC, a public campaign-finance record.

Related

Why the labels? The graph is only worth anything if the links are trusted. Facts taken straight from a federal filing are Source; figures we calculate are Computed; links we infer (corporate parents, districts, similar contractors, connections between records) are Inferred, worded carefully, never asserted as fact and never a claim that one thing caused another. Spot an error? Tell us.